Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Resmetirom in Post-Liver Transplant Patients With MASH
NCT07335601Phase 2Recruiting
- Sponsor
- Madrigal Pharmaceuticals
- Start
- Dec 2025
- Primary completion
- Aug 2028
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of resmetirom in metabolic dysfunction-associated steatohepatitis (MASH), sponsored by Madrigal Pharmaceuticals. Started Dec 2025; status: recruiting.
02
Drugs
resmetirom
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on NCT07335601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07335601.